The estimated Net Worth of Venture Fund V Lpatlas Vent... is at least $35 Milion dollars as of 27 May 2004. Venture Vent owns over 445,000 units of Alnylam Pharmaceuticals Inc stock worth over $34,965,247 and over the last 20 years Venture sold ALNY stock worth over $0.
Venture has made over 1 trades of the Alnylam Pharmaceuticals Inc stock since 2004, according to the Form 4 filled with the SEC. Most recently Venture bought 445,000 units of ALNY stock worth $2,670,000 on 27 May 2004.
The largest trade Venture's ever made was buying 445,000 units of Alnylam Pharmaceuticals Inc stock on 27 May 2004 worth over $2,670,000. On average, Venture trades about 222,500 units every 0 days since 2004. As of 27 May 2004 Venture still owns at least 133,501 units of Alnylam Pharmaceuticals Inc stock.
You can see the complete history of Venture Vent stock trades at the bottom of the page.
Over the last 20 years, insiders at Alnylam Pharmaceuticals Inc have traded over $140,068,015 worth of Alnylam Pharmaceuticals Inc stock and bought 4,419,116 units worth $1,983,132,563 . The most active insiders traders include Sanofi, Christoph H Westphal a Kevin P Starr. On average, Alnylam Pharmaceuticals Inc executives and independent directors trade stock every 23 days with the average trade being worth of $11,181,724. The most recent stock trade was executed by Yvonne Greenstreet on 20 August 2024, trading 15,000 units of ALNY stock currently worth $1,275,000.
alnylam is developing an entirely new class of innovative medicines based on a breakthrough discovery in biology known as rna interference, or rnai. with rnai technology, we have the opportunity to treat disease and impact the lives of patients in a fundamentally new way by silencing disease-causing genes upstream of today's medicines.
Alnylam Pharmaceuticals Inc executives and other stock owners filed with the SEC include: